Press releaseGlobe Newswire
Opus Genetics
IRD · NASDAQ
$4.01+$0.19 (+4.97%)TodayMarket closed ·
Prev close $3.82
Latest news
- NewsAvi Kapoor
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Big Pharma Setbacks Create a New Wave of Rebound Plays
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Crude Oil Jumps Over 3%; Core & Main Posts Upbeat Q2 Earnings
- Press releaseGlobe Newswire
Four Biotech Stories Heating Up Right Now
- NewsVandana Singh
Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says
- NewsAvi Kapoor
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday
- NewsAvi Kapoor
Dow Tumbles 350 Points; Signet Jewelers Shares Jump Following Upbeat Q2 Earnings
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
- Press releaseGlobe Newswire
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
- Press releaseGlobe Newswire
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
- News
Earnings Scheduled For May 12, 2026
- News
Opus Genetics Announces New Clinical And Preclinical Data From Multiple Programs Presented At Association For Research In Vision And Opthalmology Annual Meeting May 3-7
- Press releaseGlobe Newswire
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
- Press releaseGlobe Newswire
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
- Press releaseGlobe Newswire
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
- News
Earnings Summary: Opus Genetics Q4
- Press releaseGlobe Newswire
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
- News
Where Opus Genetics Stands With Analysts
- News
Where Opus Genetics Stands With Analysts
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseGlobe Newswire
Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness
- NewsVandana Singh
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review
- News
Market-Moving News for June 26th
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.